Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting

Detalhes bibliográficos
Autor(a) principal: Espíndola, Otávio Melo
Data de Publicação: 2023
Outros Autores: Fuller, Trevon L., Araújo, Mia Ferreira de, Tort, Luis Fernando Lopez, Guaraldo, Lusiele, Calvet, Guilherme, Resende, Paola, Bonaldo, Myrna, Whitworth, Jimmy, Smith, Chris, Siqueira, Marilda, Brasil, Patrícia
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/60233
Resumo: UK Research and Innovation MR/V033530/1, Conselho Nacional de Desenvolvimento Científco e Tecnológico PQ 311562/2021-3; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro COVID: E-26/210.146/2020, EMERGENTES: 26/211.565/2019, and CNE: E-26/200.935/2022; Unidade de Apoio ao Diagnóstico da Covid-19 (UNADIG-RJ); Fiocruz Vice-Presidência de Produção e Inovação em Saúde (VPPIS); Labi Exames
id CRUZ_6fab5ac2dfb3fcf6c3498df8ee9f8e71
oai_identifier_str oai:www.arca.fiocruz.br:icict/60233
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Espíndola, Otávio MeloFuller, Trevon L.Araújo, Mia Ferreira deTort, Luis Fernando LopezGuaraldo, LusieleCalvet, GuilhermeResende, PaolaBonaldo, MyrnaWhitworth, JimmySmith, ChrisSiqueira, MarildaBrasil, Patrícia2023-08-25T23:00:42Z2023-08-25T23:00:42Z2023ESPÍNDOLA, Otávio Melo et al. Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting. Scientific Reports, v. 13, p. 1-7, May 2023.2045-2322https://www.arca.fiocruz.br/handle/icict/6023310.1038/s41598-023-34035-92045-2322UK Research and Innovation MR/V033530/1, Conselho Nacional de Desenvolvimento Científco e Tecnológico PQ 311562/2021-3; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro COVID: E-26/210.146/2020, EMERGENTES: 26/211.565/2019, and CNE: E-26/200.935/2022; Unidade de Apoio ao Diagnóstico da Covid-19 (UNADIG-RJ); Fiocruz Vice-Presidência de Produção e Inovação em Saúde (VPPIS); Labi ExamesOswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.Institute of the Environment and Sustainability. University of California Los Angeles. Los Angeles, USA.Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil.Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil / Laboratory of Molecular Virology. Biological Sciences Department. Universidad de la República. Salto, Uruguay.Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil.Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Molecular Biology. Rio de Janeiro, RJ, Brazil.Department of Clinical Research. London School of Hygiene and Tropical Medicine. London, WC1E 7HT, UK.Department of Clinical Research. London School of Hygiene and Tropical Medicine. London, WC1E 7HT, UK.Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles National Influenza Centre (GISRS-WHO)-Americas Regional Reference Lab for Measles. Rubella-Reference Laboratory for COVID-19 (WHO). Rio de Janeiro, RJ, Brazil.Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.COVID-19 vaccines have dramatically reduced rates of severe infection requiring hospitalization. However, SARS-CoV-2 variants have reduced vaccine effectiveness at preventing any symptomatic infection. This real-world study analyzed binding and neutralizing antibodies generated after complete vaccination and boosting across three vaccine platforms. Binding antibodies decayed most slowly in people under 60 with hybrid immunity. Neutralizing antibodies against Omicron BA.1 were reduced compared to other variants. The anamnestic anti-spike IgG response to the first boost was more pronounced than after the second boost. Monitoring of the effects of SARS-CoV-2 mutations on disease severity and the effectiveness of therapeutics is warranted.engNature Publishing GroupReduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boostinginfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleCOVID-19Omicron variantComplete vaccinationBNT162b2ChAdOx1CoronaVacVaccineinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/60233/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALve_Otávio_Espíndola_etal_INI_IOC_2023.pdfve_Otávio_Espíndola_etal_INI_IOC_2023.pdfapplication/pdf2626904https://www.arca.fiocruz.br/bitstream/icict/60233/2/ve_Ot%c3%a1vio_Esp%c3%adndola_etal_INI_IOC_2023.pdf7d804f4e6f26a7bee872965e25607c07MD52icict/602332023-09-14 15:46:13.676oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-09-14T18:46:13Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
title Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
spellingShingle Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
Espíndola, Otávio Melo
COVID-19
Omicron variant
Complete vaccination
BNT162b2
ChAdOx1
CoronaVac
Vaccine
title_short Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
title_full Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
title_fullStr Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
title_full_unstemmed Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
title_sort Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
author Espíndola, Otávio Melo
author_facet Espíndola, Otávio Melo
Fuller, Trevon L.
Araújo, Mia Ferreira de
Tort, Luis Fernando Lopez
Guaraldo, Lusiele
Calvet, Guilherme
Resende, Paola
Bonaldo, Myrna
Whitworth, Jimmy
Smith, Chris
Siqueira, Marilda
Brasil, Patrícia
author_role author
author2 Fuller, Trevon L.
Araújo, Mia Ferreira de
Tort, Luis Fernando Lopez
Guaraldo, Lusiele
Calvet, Guilherme
Resende, Paola
Bonaldo, Myrna
Whitworth, Jimmy
Smith, Chris
Siqueira, Marilda
Brasil, Patrícia
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Espíndola, Otávio Melo
Fuller, Trevon L.
Araújo, Mia Ferreira de
Tort, Luis Fernando Lopez
Guaraldo, Lusiele
Calvet, Guilherme
Resende, Paola
Bonaldo, Myrna
Whitworth, Jimmy
Smith, Chris
Siqueira, Marilda
Brasil, Patrícia
dc.subject.en.en_US.fl_str_mv COVID-19
Omicron variant
Complete vaccination
BNT162b2
ChAdOx1
CoronaVac
Vaccine
topic COVID-19
Omicron variant
Complete vaccination
BNT162b2
ChAdOx1
CoronaVac
Vaccine
description UK Research and Innovation MR/V033530/1, Conselho Nacional de Desenvolvimento Científco e Tecnológico PQ 311562/2021-3; Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro COVID: E-26/210.146/2020, EMERGENTES: 26/211.565/2019, and CNE: E-26/200.935/2022; Unidade de Apoio ao Diagnóstico da Covid-19 (UNADIG-RJ); Fiocruz Vice-Presidência de Produção e Inovação em Saúde (VPPIS); Labi Exames
publishDate 2023
dc.date.accessioned.fl_str_mv 2023-08-25T23:00:42Z
dc.date.available.fl_str_mv 2023-08-25T23:00:42Z
dc.date.issued.fl_str_mv 2023
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ESPÍNDOLA, Otávio Melo et al. Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting. Scientific Reports, v. 13, p. 1-7, May 2023.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/60233
dc.identifier.issn.en_US.fl_str_mv 2045-2322
dc.identifier.doi.none.fl_str_mv 10.1038/s41598-023-34035-9
dc.identifier.eissn.none.fl_str_mv 2045-2322
identifier_str_mv ESPÍNDOLA, Otávio Melo et al. Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting. Scientific Reports, v. 13, p. 1-7, May 2023.
2045-2322
10.1038/s41598-023-34035-9
url https://www.arca.fiocruz.br/handle/icict/60233
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/60233/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/60233/2/ve_Ot%c3%a1vio_Esp%c3%adndola_etal_INI_IOC_2023.pdf
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
7d804f4e6f26a7bee872965e25607c07
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008871401193472

Registros relacionados